David M. Polen
Polen Capital Management
Polen Capital Management Cytokinetics Inc stake
total: 588
Polen Capital Management CYTK trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2025 Q4
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q1
According to 2026 Q2 report, Polen Capital Management doesn't hold any Cytokinetics Inc (CYTK) shares. To date, the estimated cost basis is nearly $63.54 for "buy" trades and estimated average "sell" price is $63.54. Polen Capital Management first purchased CYTK in 2025 Q4, initially acquiring 9,584 shares. Since the initial investment in Cytokinetics Inc (CYTK), Polen Capital Management has made 1 more transaction.
When did Polen Capital Management sell Cytokinetics Inc (CYTK)?
Polen Capital Management sold off the entire Cytokinetics Inc (CYTK) position in 2026 Q1.
When did Polen Capital Management buy Cytokinetics Inc (CYTK)?
Polen Capital Management first invested in Cytokinetics Inc (CYTK) in 2025 Q4 at the reported quarter-end price of $63.54 per share.
What's the cost basis of Polen Capital Management's CYTK stake?
The estimated cost basis for Cytokinetics Inc (CYTK) stake is around $63.54 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $63.54
- Weighted AVG sell price:
- $63.54
Polen Capital Management's historical trades in Cytokinetics Inc
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.00%
|
0
|
$63.54
|
|
-100% (-9,584)
|
-0%
|
|
2025 Q4
|
0.00%
|
9,584
|
$63.54
|
$608,967
|
new
|
+0%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.